Insulin-like growth factor binding protein 7 for treatment of cancer
AssigneeUniversity of Massachusetts
InventorsMichael Green, Narendra Wajapeyee
Life of this patent
Estimating the term…
Abstract
Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS.
Claims28
A method of treating a tumor in a subject, the method comprising:
- identifying a subject having, at risk for, or suspected of having a tumor;
- determining that a cell of the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS;
- and
- administering to the subject an effective amount of an IGFBP7 agent, thereby treating the tumor.
A method of inhibiting proliferation of a cell that has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS, the method comprising administering to the cell an effective amount of an IGFBP7 agent.
-24. (canceled)
A method of diagnosing a melanocytic skin lesion, the method comprising:
- obtaining a sample of a melanocytic skin lesion;
- determining expression of IGFBP7 in the sample;
- and
- determining whether the sample contains an activated BRAF or RAS;
- diagnosing the lesion as a melanocytic nevus if the sample expresses IGFBP7 and contains an activated BRAF or RAS,
- diagnosing the lesion as a melanoma if the sample does not express IGFBP7 and contains an activated BRAF or RAS, and
- diagnosing the lesion as a melanoma if the sample expresses IGFBP7 and does not contain an activated BRAF or RAS.
A method of treating a melanoma in a subject, the method comprising:
- identifying a subject having, at risk for, or suspected of having a melanoma;
- and
- administering to the subject an effective amount of an IGFBP7 agent, thereby treating the melanoma.
Dependencies are inferred from the claim text.